Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Keytruda plus Lenvima is an option for advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-based chemo in any setting ...

so far as it is the only regimen so far with long-term survival data (48 months-plus) in patients with a poorer prognosis. Approval of the Keytruda-Lenvima regimen would be a win-win for Merck ...

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Get the best Black Friday deals direct to your inbox, plus news, reviews, and more. Sign up to be the first to know about unmissable Black Friday deals on top tech, plus get all your favorite ...

If you’re a frequent Walmart shopper, the perks of a Walmart Plus membership — like free unlimited deliveries and mobile scan and go– can save you time and money, especially during Black ...

One of Disney Plus’ big selling points when it launched in 2019 was its vast back catalog of movies, yet its TV offering was unlikely to compete with the likes of Netflix. Nowadays, however ...